Anaptys Announces Stock Repurchase Plan
AnaptysBio (ANAB) has announced a $75 million Stock Repurchase Plan authorized by its Board of Directors. The clinical-stage biotechnology company maintains a strong financial position with over $420 million in cash, cash equivalents, and investments as of December 31, 2024.
The company expects to receive a $75 million commercial sales milestone payment from GSK in 2025 or 2026. Despite the potential full execution of the buyback plan, AnaptysBio reaffirms its cash runway guidance through year-end 2027 for its R&D plan, excluding future royalties from its GSK immuno-oncology collaboration.
The stock repurchase program will run through December 31, 2025, with shares to be bought in open market transactions under Rules 10b5-1 and 10b-18. The company maintains flexibility to suspend or discontinue the program at any time.
AnaptysBio (ANAB) ha annunciato un piano di riacquisto azionario da 75 milioni di dollari autorizzato dal suo Consiglio di Amministrazione. L'azienda biotecnologica in fase clinica mantiene una solida posizione finanziaria con oltre 420 milioni di dollari in contante, equivalenti di cassa e investimenti al 31 dicembre 2024.
L'azienda prevede di ricevere un pagamento per traguardo di vendite commerciali da 75 milioni di dollari da GSK nel 2025 o 2026. Nonostante la potenziale piena attuazione del piano di riacquisto, AnaptysBio conferma la sua guida sulla liquidità fino alla fine del 2027 per il suo piano di R&D, escludendo le future royalty dalla collaborazione immuno-oncologica con GSK.
Il programma di riacquisto azionario si svolgerà fino al 31 dicembre 2025, con azioni da acquistare in transazioni sul mercato aperto secondo le Regole 10b5-1 e 10b-18. L'azienda mantiene la flessibilità di sospendere o interrompere il programma in qualsiasi momento.
AnaptysBio (ANAB) ha anunciado un plan de recompra de acciones de 75 millones de dólares autorizado por su Junta Directiva. La empresa biotecnológica en etapa clínica mantiene una sólida posición financiera con más de 420 millones de dólares en efectivo, equivalentes de caja e inversiones al 31 de diciembre de 2024.
La compañía espera recibir un pago por hito de ventas comerciales de 75 millones de dólares de GSK en 2025 o 2026. A pesar de la posible ejecución completa del plan de recompra, AnaptysBio reafirma su guía de liquidez hasta finales de 2027 para su plan de I+D, excluyendo regalías futuras de su colaboración en inmuno-oncología con GSK.
El programa de recompra de acciones se llevará a cabo hasta el 31 de diciembre de 2025, con acciones que se comprarán en transacciones en el mercado abierto bajo las Reglas 10b5-1 y 10b-18. La empresa mantiene la flexibilidad para suspender o interrumpir el programa en cualquier momento.
AnaptysBio (ANAB)는 이사회에서 승인한 7500만 달러 규모의 자사주 매입 계획을 발표했습니다. 이 임상 단계의 생명공학 회사는 2024년 12월 31일 기준으로 4억 2000만 달러 이상의 현금, 현금성 자산 및 투자를 보유하고 있습니다.
회사는 2025년 또는 2026년에 GSK로부터 7500만 달러의 상업 판매 이정표 지급액을 받을 것으로 예상하고 있습니다. 자사주 매입 계획의 완전한 실행 가능성에도 불구하고, AnaptysBio는 GSK와의 면역 종양학 협업에서 발생하는 향후 로열티를 제외하고 2027년 연말까지 R&D 계획을 위한 현금 운영 지침을 재확인합니다.
자사주 매입 프로그램은 2025년 12월 31일까지 진행되며, 10b5-1 및 10b-18 규정에 따라 공개 시장 거래에서 주식을 매입합니다. 회사는 언제든지 프로그램을 중단하거나 종료할 수 있는 유연성을 유지합니다.
AnaptysBio (ANAB) a annoncé un plan de rachat d'actions de 75 millions de dollars autorisé par son Conseil d'administration. La société biopharmaceutique en phase clinique maintient une solide position financière avec plus de 420 millions de dollars en liquidités, équivalents de liquidités et investissements au 31 décembre 2024.
La société s'attend à recevoir un paiement d'étape de vente commerciale de 75 millions de dollars de GSK en 2025 ou 2026. Malgré la possibilité d'une exécution complète du plan de rachat, AnaptysBio réaffirme ses prévisions de liquidités jusqu'à la fin de 2027 pour son plan de R&D, excluant les redevances futures de sa collaboration en immuno-oncologie avec GSK.
Le programme de rachat d'actions se déroulera jusqu'au 31 décembre 2025, avec des actions à acheter dans le cadre de transactions sur le marché ouvert conformément aux règles 10b5-1 et 10b-18. L'entreprise conserve la flexibilité de suspendre ou d'arrêter le programme à tout moment.
AnaptysBio (ANAB) hat einen Aktienrückkaufplan über 75 Millionen Dollar angekündigt, der von seinem Vorstand genehmigt wurde. Das biopharmazeutische Unternehmen in der klinischen Phase verfügt über eine starke finanzielle Basis mit über 420 Millionen Dollar an Bargeld, Zahlungsmitteläquivalenten und Investitionen zum 31. Dezember 2024.
Das Unternehmen erwartet, im Jahr 2025 oder 2026 eine Meilensteinzahlung für kommerzielle Verkäufe in Höhe von 75 Millionen Dollar von GSK zu erhalten. Trotz der möglichen vollständigen Umsetzung des Rückkaufplans bekräftigt AnaptysBio seine Liquiditätsprognose bis Ende 2027 für seinen F&E-Plan, ohne zukünftige Lizenzgebühren aus der Zusammenarbeit mit GSK im Bereich Immunonkologie.
Das Aktienrückkaufprogramm läuft bis zum 31. Dezember 2025, wobei die Aktien im Rahmen von Transaktionen auf dem offenen Markt gemäß den Regeln 10b5-1 und 10b-18 gekauft werden. Das Unternehmen behält sich die Flexibilität vor, das Programm jederzeit auszusetzen oder einzustellen.
- Strong cash position of over $420 million
- Additional $75M milestone payment expected from GSK
- Stock buyback program indicates confidence in company value
- Confirmed cash runway through 2027 despite buyback
- Potential future royalties from GSK collaboration not included in guidance
- Buyback reduces cash available for R&D investments
- Program may not be fully executed if market conditions are unfavorable
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to
Anaptys has cash, cash equivalents and investments greater than
The shares may be repurchased from time to time in open market transactions, or other means in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Rule 10b-18 of the Exchange Act. The timing, number of shares repurchased, and prices paid for the stock under this program will depend on general business and market conditions as well as corporate and regulatory limitations, prevailing stock prices, and other considerations. The Stock Repurchase Plan will expire on December 31, 2025, may be suspended or discontinued at any time, and does not obligate the company to acquire any amount of common stock.
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a depleter and agonist targeting PD-1+ T cells, is in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis. Other antibodies in its portfolio include ANB033, a CD122 antagonist, in a Phase 1 trial and ANB101, a BDCA2 modulator, entering a Phase 1 trial. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the company’s ability to execute the Stock Repurchase Plan, in whole or in part; the company’s projected cash runway, and the potential to receive any additional milestones or royalties from the GSK collaboration. Statements including words such as “plan,” “continue,” “expect,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company’s ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company’s ability to fund development activities and achieve development goals, the company’s ability to protect intellectual property and other risks and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
Contact:
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
investors@anaptysbio.com
FAQ
How much is AnaptysBio's (ANAB) stock repurchase program worth?
When will ANAB's stock buyback program expire?
What is AnaptysBio's (ANAB) current cash position as of December 2024?
What milestone payment does ANAB expect from GSK?
How long does ANAB expect its cash runway to last?
